The Ensign Group, Inc. (NASDAQ:ENSG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective November 28, 2018, the Board of Directors (the “Board”) of The Ensign Group, Inc. (the “Company”) appointed Dr. Ann Scott Blouin to fill the vacancy created by the resignation of, Malene Davis on August 4, 2018. Dr. Blouin recently retired from her position as Executive Vice President of Customer Relations at The Joint Commission where she provided leadership in aligning the strategic and operating goals of the organization with its client base. With more than 30 years of health care administration, consulting and clinical nursing experience, Dr. Blouin has held key senior leadership positions at community teaching hospitals and academic medical centers. While serving in key leadership roles with the consulting firms of Deloitte, Ernst & Young, Cap Gemini and Huron Consulting Group, she worked with multiple health systems across the United States and Canada to help them improve operating cost efficiency and effectiveness, revenue management, care coordination, and quality and patient safety. Dr. Blouin is currently serving as President of PSQ Advisory, working with the board and senior leadership to deliver strategic guidance to America's health systems. In addition, Dr. Blouin also serves on the Institute for Healthcare Improvement Board of Directors and as an editorial advisor for theJournal of Nursing AdministrationandAmerican Nurse Today. Dr. Blouin earned her Doctor of Philosophy (PhD) in Nursing Sciences and Masters Degrees in Business Administration (MBA) from the University of Illinois at Chicago. Dr. Blouin received her Master of Science in Nursing (MSN) from Loyola University of Chicago, and Bachelor of Science in Nursing (BSN) from Lewis University in Romeoville, Illinois.
Dr. Blouin’s appointment to the Board was made at the recommendation of the Nomination and Corporate Governance Committee, which anticipates appointing Dr. Blouin to certain committees of the board at their next scheduled meeting.
Dr. Blouin's compensation for her services as a director will be consistent with that of the Company’s other non-employee directors, as described in the Company’s proxy statement for its 2018 annual meeting of stockholders filed with the Securities and Exchange Commission on April 12, 2018. There are no arrangements or understandings between Dr. Blouin and any other persons to which Dr. Blouin was selected as a director, and there are no transactions in which Dr. Blouin has an interest requiring disclosure under Item 404(a) of Regulation S-K.
About The Ensign Group, Inc. (NASDAQ:ENSG)
The Ensign Group, Inc. is a holding company. The Company, through its subsidiaries, provides healthcare services across the post-acute care continuum, as well as urgent care centers and mobile ancillary businesses. Its segments include transitional, skilled and assisted living services (TSA services); home health and hospice services, and all other. The TSA services segment includes the operation of skilled nursing facilities and assisted and independent living facilities. The home health and hospice services segment includes the Company’s home health, home care and hospice businesses. The all other segment includes the Company’s urgent care centers and mobile ancillary operations. The Company operates a portfolio to approximately 207 healthcare facilities, over 35 of which are owned, approximately 16 hospice agencies, over 16 home health agencies, approximately three home care businesses and over 17 urgent care clinics across approximately 14 states.
